256 related articles for article (PubMed ID: 10199224)
1. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study.
Lyles RH; Chu C; Mellors JW; Margolick JB; Detels R; Giorgi JV; Al-Shboul Q; Phair JP
AIDS; 1999 Feb; 13(3):341-9. PubMed ID: 10199224
[TBL] [Abstract][Full Text] [Related]
2. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections.
Williams PL; Currier JS; Swindells S
AIDS; 1999 Jun; 13(9):1035-44. PubMed ID: 10397533
[TBL] [Abstract][Full Text] [Related]
3. Patterns of opportunistic infections in patients with HIV infection.
Finkelstein DM; Williams PL; Molenberghs G; Feinberg J; Powderly WG; Kahn J; Dolin R; Cotton D
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):38-45. PubMed ID: 8624759
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
6. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
7. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
9. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
10. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.
Asch SM; Gifford AL; Bozzette SA; Turner B; Mathews WC; Kuromiya K; Cunningham W; Andersen R; Shapiro M; Rastegar A; McCutchan JA
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):340-4. PubMed ID: 11707670
[TBL] [Abstract][Full Text] [Related]
11. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.
Dore GJ; Hoy JF; Mallal SA; Li Y; Mijch AM; French MA; Cooper DA; Kaldor JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):39-43. PubMed ID: 9377123
[TBL] [Abstract][Full Text] [Related]
12. [The new age of HIV/AIDS. A special report on the XI International Conference on AIDS].
Detres LL
Sidahora; 1996; ():26-33. PubMed ID: 11364380
[TBL] [Abstract][Full Text] [Related]
13. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Jacobson MA; French M
AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
[TBL] [Abstract][Full Text] [Related]
14. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS.
Chan IS; Neaton JD; Saravolatz LD; Crane LR; Osterberger J
AIDS; 1995 Oct; 9(10):1145-51. PubMed ID: 8519450
[TBL] [Abstract][Full Text] [Related]
15. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.
Coakley EP; Samore MH; Gillis JM; Hughes MD; Hammer SM
AIDS; 2000 Jun; 14(9):1147-53. PubMed ID: 10894278
[TBL] [Abstract][Full Text] [Related]
16. Stopping preventive treatments.
Fornataro K; Jefferys R
Body Posit; 1999 Jul; 12(7):9-10. PubMed ID: 11367080
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
[TBL] [Abstract][Full Text] [Related]
18. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
19. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
[TBL] [Abstract][Full Text] [Related]
20. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
